Masimo Corporation Stock Upgraded (MASI)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Masimo Corporation (Nasdaq: MASI) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, increase in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 1.3%. Since the same quarter one year prior, revenues rose by 14.0%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • MASI's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, MASI has a quick ratio of 1.63, which demonstrates the ability of the company to cover short-term liquidity needs.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, MASIMO CORP's return on equity exceeds that of both the industry average and the S&P 500.
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Health Care Equipment & Supplies industry average. The net income increased by 4.1% when compared to the same quarter one year prior, going from $15.77 million to $16.43 million.
  • Net operating cash flow has slightly increased to $25.10 million or 7.97% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -27.93%.
.

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive patient monitoring products worldwide. The company has a P/E ratio of 20.5, above the S&P 500 P/E ratio of 17.7. Masimo has a market cap of $1.25 billion and is part of the health care sector and health services industry. Shares are up 5.4% year to date as of the close of trading on Tuesday.

You can view the full Masimo Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Masimo: Cramer's Top Takeaways

Earnings Are Still Calling the Tune: Cramer's 'Mad Money' Recap (Friday 5/12/17)

These Stocks Are Changing Course